paediatrics Brussels 17

Group 4 Medulloblastoma

• Intermediate to good prognosis similar to patients with SHH tumours • Include classical and large cell/anaplastic histologies • Approx 30–40% of MB cases • M:F ratio 3:1 • Molecular pathogenesis not currently clear